ストックスクリーナーアプリを入手
6.07
0.82%
-0.05
プレマーケット:
6.07
前日終値:
$6.12
開ける：
$5.9511
24時間の取引高:
286.64K
Relative Volume:
0.22
時価総額：
$166.42M
収益：
$160.43M
当期純損益:
$-227.64M
株価収益率:
-0.0883
EPS:
-68.77
ネットキャッシュフロー:
$-170.79M
1週間 パフォーマンス:
-4.56%
1か月 パフォーマンス:
+26.46%
6か月 パフォーマンス:
+61.44%
1年 パフォーマンス:
-12.16%
1日の値動き範囲:
$5.90
$6.21
1週間の範囲:
$5.67
$6.96
52週間の値動き範囲:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
AGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
6.07 | 167.79M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 開始されました | Robert W. Baird | Outperform |
| 2023-02-28 | 再開されました | H.C. Wainwright | Buy |
| 2022-09-28 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 再開されました | B. Riley FBR | Buy |
| 2019-04-22 | 開始されました | B. Riley FBR | Buy |
| 2016-10-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 繰り返されました | Maxim Group | Buy |
| 2016-03-11 | アップグレード | Maxim Group | Hold → Buy |
| 2015-12-16 | 開始されました | Jefferies | Buy |
| 2015-10-27 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-07-27 | 繰り返されました | MLV & Co | Buy |
| 2015-06-11 | 開始されました | Oppenheimer | Outperform |
| 2015-01-12 | 繰り返されました | Maxim Group | Buy |
| 2015-01-09 | 繰り返されました | MLV & Co | Buy |
| 2015-01-09 | 繰り返されました | Maxim Group | Buy |
| 2014-12-19 | 繰り返されました | Maxim Group | Buy |
| 2014-05-08 | 繰り返されました | Maxim Group | Buy |
| 2014-03-14 | 繰り返されました | MLV & Co | Buy |
| 2013-10-08 | 繰り返されました | Maxim Group | Buy |
| 2012-01-05 | 開始されました | William Blair | Outperform |
| 2011-12-01 | 開始されました | Global Hunter Securities | Buy |
すべてを表示
Agenus Inc (AGEN) 最新ニュース
Is Agenus Inc. a good long term investmentExceptional growth trajectory - Autocar Professional
What analysts say about Agenus Inc. stockFree Capital Efficiency Planning - Autocar Professional
Agenus Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
What drives Agenus Inc. stock priceAccelerated investment success - jammulinksnews.com
AI Revolution in Healthcare: Avant Technologies, Agenus, Clover Health, Zimmer Biomet, Monogram Technologies Lead the Way. - AInvest
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits - Finansavisen
Colon cancer impacts far more than just the body – Agenus - Oncodaily
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Zydus Lifesciences receives final approval from USFDA for Celecoxib Capsules - MarketScreener
AGEN Stock Outpaces Medical Sector Peers This Year - AInvest
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains? - Yahoo Finance
Public Companies Hold Majority of MiNK Therapeutics Stock After 815% Gain - AInvest
Agenus Responds to New Regulatory Environment at FDA - Oncodaily
Agenus Inc. shares surge 19.54% intraday after positive clinical data and strategic partnership. - AInvest
Zacks.com featured highlights Yext, Agenus and NCR Voyix - The Globe and Mail
Agenus stock maintains Buy rating at H.C. Wainwright after positive bot/bal data - Investing.com Canada
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts - Baystreet.ca
Agenus stock maintains Buy rating at H.C. Wainwright after positive bot/bal data By Investing.com - Investing.com South Africa
Agenus Inc. shares fall 1.35% in after-hours trading after FDA questions efficacy data for BOT/BAL combination. - AInvest
Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial - Oncodaily
Agenus' BOT/BAL in MSS CRC: A Breakthrough with Accelerated Approval on the Horizon? - AInvest
Agenus reports 42% two-year survival in colorectal cancer trial - Investing.com
Agenus' BOT/BAL Combo Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward FDA Registration with Phase 3 Trial Design Alignment. - AInvest
42% Survival Rate: Agenus Cancer Drug Shows Breakthrough in Resistant Colorectal Cancer | AGEN Stock News - Stock Titan
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Agenus Inc. shares surge 8.17% intraday after HC Wainwright & Co. analyst upgrades rating to strong buy. - AInvest
Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN
Agenus Requests to Dismiss Class Action Filed by Investors - TradingView
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell Small Cap Completeness Index - MarketScreener
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell 2000 Growth Index - MarketScreener
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell 2000 Dynamic Index - MarketScreener
2 East Bay drugmaking sites sold to Indian manufacturer - The Business Journals
# Agenus and Noetik partner to develop AI-powered cancer treatment biomarkers - Investing.com India
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - MSN
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo - MarketScreener
Agenus (AGEN) and Noetik Collaborate to Enhance Cancer Treatment - GuruFocus
Agenus, Noetik Enter Research Collaboration - Nasdaq
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology | AGEN Stock News - GuruFocus
AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan
10 Most Undervalued Stocks to Buy for Under $5 - Insider Monkey
Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire Inc.
Is Zydus’s Agenus Deal Opportunistic Or Strategic? - insights.citeline.com
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Agenus Announces Virtual Annual Shareholders Meeting - New Castle News
How to Join Agenus 2025 Virtual Shareholders Meeting: Complete Registration Guide - Stock Titan
Agenus Inc (AGEN) 財務データ
収益
当期純利益
現金流量
EPS
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):